Editorial
|
|
|
|
|
Beware selective excerpts from the SPC
|
|
|
|
New Products
|
|
|
|
|
Longer follow-up, but still no proven advantage
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highly toxic, limited efficacy
|
|
|
|
|
|
|
|
|
|
Do not use instead of, or with, a beta-blocker
|
|
|
|
|
|
|
|
|
|
Just another TNF alpha antagonist, no therapeutic advantage
|
|
|
|
|
|
|
|
|
|
Also avoid its use in recurrent depression
|
|
|
|
Adverse Effects
|
|
|
|
|
Evidence of increased risk
|
|
|
|
|
|
|
|
|
|
Do not use in women without membrane rupture or infection
|
|
|
|
|
|
|
|
|
|
|
|
A French pharmacovigilance survey
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outlook
|
|
|
|
|
Hidden by drug companies, withheld by Food and Drug Administration
|
|
|
|
|
|
|
|
|
|
French diabetes patient group unhappy with Prescrire
|
|
|
|
|
|
|
|
|
|
Annual Prescrire Prize ceremony 2010
|
|
|
|
|
|